Cartalax is a synthetic peptide of three amino acids, a tripeptide, and one of the short peptide bioregulators, a class of small peptides designed to adjust tissue function. It belongs to a family of short peptides, two to seven amino acids long, that Vladimir Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia designed from the amino acid composition of organ extracts [12][14][22]. Its natural counterpart occurs in cartilage tissue: a polypeptide complex isolated from bovine cartilage contains it, and that complex is studied alongside the synthetic peptide [2]. The closest familiar relative is Epitalon, a four-amino-acid peptide from the same program that is studied for neuroendocrine function, circadian rhythm and aging [14].
Cartalax's research history starts with the Khavinson short-peptide program, and the earliest study of the tripeptide cited here appeared in 2007, when Povorozniuk, Khavinson and colleagues tested a cartilage-tissue preparation and the tripeptide in aging rats after ovariectomy, the surgical removal of the ovaries [1]. The paper reported that both protected bone mineral density, a measure of how much mineral is packed into bone, and that the cartilage preparation was stronger [1]. The tripeptide's appeal is tissue focus: cartilage cells and skin fibroblasts, the cells that make collagen, respond to it in culture, meaning cells grown outside the body [2][7], and bone defects form a more mature regenerate in old rats [13], while the same family includes peptides aimed at the immune system, liver and heart [14]. That family context matters because a three-amino-acid peptide is small enough to synthesize and study in many cell types, but its small size also makes selectivity hard to prove.
In cultured chondrocytes, the cells that build cartilage, the tripeptide increased cell numbers [2], and in aging human mesenchymal stem cells it raised expression of the cartilage genes SOX9, aggrecan, type II collagen and COMP [4]. It also normalized markers of the senescence-associated secretory phenotype, the inflammatory mix that aging cells release, in chondrocytes [3]. As of October 2026, Cartalax is not on FDA's 503A bulk substances list, the list of substances pharmacies may use in compounding, and has no registered clinical trial listed on ClinicalTrials.gov [19][20]; Drugs@FDA lists no approved Cartalax product [21]. One controlled study in periodontitis included Cartalax capsules in some groups as part of a multi-drug regimen, so human evidence for the peptide alone is still missing [6]. The COA library is the place to check identity and purity data for research material.
Key takeaways
- Cartalax is a synthetic tripeptide of three amino acids, developed in Vladimir Khavinson's short-peptide program [12][14]. It is studied mainly for cartilage, bone and cell aging [1][3][5].
- In cell and animal studies it increased chondrocyte growth, normalized aging markers in cartilage cells, and improved bone regeneration in old rats [2][3][13].
- As of October 2026, it is not on FDA's 503A list and has no registered clinical trial listed on ClinicalTrials.gov; one controlled periodontal study included it in some groups in a multi-drug regimen, so its own effect in humans is unmeasured [6][19][20].
How it works
Chondrocyte growth and the cartilage matrix
Cartalax's best-supported action is on chondrocytes, the cells that build and maintain cartilage. In primary cultures from rat intervertebral discs, the tripeptide raised cell numbers at 200 ng/ml, and the effect was larger in cells from old animals [2]. A primary culture is made from cells taken directly from tissue, and an intervertebral disc is the cartilage pad between the bones of the spine.
The 2023 study used 3-month-old and 20-month-old rats and counted cells on days 2 through 5. At 200 ng/ml, Cartalax increased chondrocyte number 1.4 to 1.8 fold in young-rat cultures and 1.6 to 2.1 fold in old-rat cultures [2]. The cartilage polypeptide complex needed 2000 ng/ml for a similar effect, which suggests the tripeptide is the more potent component on a per-weight basis [2]. The paper reports p<0.01 versus control but no group sizes.
A second 2023 study asked whether the peptide pushes stem cells toward cartilage. Mesenchymal stem cells are adult stem cells that can become bone, fat or cartilage, and SOX9 is the master transcription factor that starts the cartilage program. At 200 ng/ml, Cartalax activated gene expression and protein synthesis of SOX9, aggrecan, type II collagen and COMP in human mesenchymal stem cells aged in culture [4]. Aggrecan and type II collagen are the main structural proteins of cartilage matrix, and COMP is a matrix protein that helps assemble collagen. The same study reported that the cartilage complex needed 2000 ng/ml [4].
The senescence program and SASP
Cartalax is studied as a geroprotector, a substance that shifts aging cells toward a younger pattern. One measure is the senescence-associated secretory phenotype, or SASP: the mix of inflammatory cytokines and growth factors that cells release when they stop dividing. In aging chondrocytes, the tripeptide normalized the synthesis of p16, p21, p53, TNF-alpha, IL-1alpha and SIRT1 [3]. p16, p21 and p53 are proteins that slow the cell cycle or push a cell toward death, SIRT1 is a longevity-linked enzyme, and TNF-alpha and IL-1alpha are inflammatory cytokines.
The same pattern appears in other cell types. In aging human skin fibroblasts, Cartalax increased SIRT1, SIRT6 and collagen I synthesis [7]. In aging kidney cell cultures, the tripeptide lowered p16, p21 and p53 and raised SIRT6 [11]. These are marker changes in cultured cells; they do not measure tissue age or lifespan, and each study comes from the same research network.
The geroprotector label has a wider evidence base in the peptide family than in Cartalax itself. A 2010 review of the program reported that long-term treatment with some peptide preparations raised mean lifespan in rodents by 20 to 40 percent and summarized 6 to 12 years of clinical use [12]. Those results are not specific to Cartalax, and no lifespan study of Cartalax alone is cited here.
Gene regulation and the DNA-binding model
The working explanation is that short peptides enter the cell nucleus and change transcription, the process of reading DNA into RNA. The Khavinson group reports that peptides of two to seven amino acids can cross the nuclear membrane and bind DNA or histone proteins, the spool proteins that package DNA [14]. A 2021 systematic review from the group lists Cartalax as a peptide that regulates cartilage and skin fibroblast function [14].
For Cartalax specifically, the direct evidence is modeling. In a 2014 study of aging kidney cells, the authors built models of the peptide docking to DNA and reported that the tripeptide forms its most favorable complex with a repeated AT sequence in the minor groove, the narrow channel that runs along the DNA double helix [11]. The same paper measured lower p16, p21 and p53 and higher SIRT6 in the cells, but the DNA binding itself came from the model, not from a solved structure [11].
A 2022 review adds a transport model. It lists Cartalax among peptides that dock to LAT1, an amino acid transporter on cell membranes, with a computed score of -26.65 [15]. LAT1 can carry some di- and tripeptides, but the Cartalax entry is a docking calculation, and no measurement of the peptide entering human cartilage is cited [15]. The target question stays open.
Bone repair, skin and the kidney
The peptide's effects reach beyond cartilage. In old rats with a standard defect in the mandible, the lower jaw bone, Kartalaks given before surgery produced a more mature bone regenerate at 60 to 120 days than control [13]. A regenerate is the new tissue that fills a wound, and the treated animals had less connective and cartilage tissue and more advanced remodeling of the new bone [13].
In the kidney, Cartalax reduced protein excretion and urinary electrolyte concentration in rats with cisplatin-induced acute renal failure [10]. Cisplatin is a chemotherapy drug that injures the kidney, and proteinuria means protein leaking into urine. The same study reported broader normalization with the kidney polypeptide complex, Ovagen and epitalon, including urine output, glomerular filtration rate and sodium reabsorption [10].
Skin fibroblasts are the cells that make collagen and maintain the dermis. In aging human fibroblasts, the tripeptide raised collagen I, SIRT1 and SIRT6 [7], and an earlier study from the same group reported lower MMP-9, higher Ki-67 and less caspase-dependent apoptosis [16]. MMP-9 is an enzyme that degrades matrix, Ki-67 marks dividing cells, and caspases are enzymes that carry out apoptosis, or programmed cell death [16].
What has been studied in humans
The human record cited here is one controlled study, and it tested a regimen rather than Cartalax alone. In 2022, Bandrivsky and colleagues compared 157 patients with generalized periodontitis against 133 controls treated conventionally [6]. Periodontitis is gum inflammation that destroys the tissue and bone holding the teeth. Patients with grade II or III disease received Cartalax capsules along with mummy balm, a peptide gel, Tsinsil-T and Olekap; the grade III groups also received Ensil, and the grade I groups received Revimite instead of Cartalax [6].
The study grouped patients by ABO blood type and by disease grade, and followed oral-fluid markers for a year. In the O(I) main group, which included grade I patients who did not receive Cartalax, total protein fell 34.27 percent and C-reactive protein fell 47.93 percent at one year, while calcium rose 92.96 percent, compared with baseline [6]. C-reactive protein is an inflammation marker, and oral fluid here means the mixed saliva sample the study analyzed [6].
The design cannot isolate Cartalax. Every patient in the main group received several products, the paper does not describe randomization or blinding, and it does not report adverse events or how safety was monitored [6]. The comparison is between a multi-drug regimen and conventional care, so the improvement belongs to the regimen as a whole [6].
A 2023 review states that the tripeptide has shown efficacy in animal osteoarthritis models and with oral use in older patients with osteoarthritis [5]. The abstract gives no trial citation, sample size or design for the human statement, and the sources reviewed here contain no such trial report [5]. That claim stays a review assertion until a primary study is produced.
No registered trial of Cartalax appears on ClinicalTrials.gov as of October 2026 [20]. The 2023 Vrach paper describes a phase 2 program for the cartilage polypeptide complex that contains the tripeptide, but that program tests the complex, not the isolated tripeptide [2].
Doses studied in human trials
As of October 2026, Cartalax remains without FDA approval for any human use and without a registered clinical trial listed on ClinicalTrials.gov. Regimens below are those reported in the cited human study.
2 capsules daily with meals for 14 days in some groups, and 2 capsules twice daily with meals for 14 days in others, alongside other products
157 patients with generalized periodontitis in the main group and 133 controls, grouped by ABO blood type and disease grade
20, 200 and 2000 ng/ml; 200 ng/ml was the effective Cartalax concentration
Chondrocytes from 3-month-old and 20-month-old rats
200 ng/ml Cartalax; 2000 ng/ml cartilage polypeptide complex
Human mesenchymal stem cells during replicative aging
Lab and animal studies
The animal work is small and concentrated in bone and kidney. In 2007, ovariectomized rats given a cartilage-tissue preparation or the T-31 tripeptide showed preserved bone mineral density, and the cartilage preparation was the stronger of the two [1]. In 2016, old rats with a standard mandibular defect received Kartalaks before surgery and formed a more mature bone regenerate at 60 to 120 days, with less connective and cartilage tissue than control [13].
The cell work fills in the cartilage picture. Primary chondrocytes from young and old rats grew faster with Cartalax at 200 ng/ml, and the effect was larger in cells from old animals [2]. In human mesenchymal stem cells aged in culture, the tripeptide at 200 ng/ml raised SOX9, aggrecan, type II collagen and COMP, the markers of chondrogenic differentiation [4]. The same peptide normalized p16, p21, p53, TNF-alpha, IL-1alpha and SIRT1 in aging chondrocytes, which is the marker pattern of a less senescent cell [3].
Other tissues show the same broad, marker-level response. Cartalax raised SIRT1, SIRT6 and collagen I in human skin fibroblasts [7], and it lowered MMP-9, raised Ki-67 and reduced caspase-dependent apoptosis in an earlier fibroblast study [16]. In kidney explants from young and old rats, T-31 stimulated proliferation and reduced apoptosis, though less than the kidney polypeptide complex [9]. In rats with cisplatin-induced acute kidney injury, the tripeptide reduced protein excretion and urinary electrolyte concentration, while the complex, Ovagen and epitalon normalized additional parameters including urine output, glomerular filtration rate and sodium reabsorption [10].
A 2020 study of three short peptides complicates the attribution. In aging human mesenchymal stem cell cultures, the study reported that IGF1 expression rose 3.5 to 5.6 fold with the peptides, and all three raised NF-kB, but the abstract reports the IGF1 change for the peptides together and does not separate Cartalax's contribution [8]. The 2021 review's gene-regulation model and the 2022 transport modeling review are explanations for these patterns, not independent tests of them [14][15].
The limits are consistent across the literature. Every primary preclinical study cited here comes from the Khavinson institute or its close collaborators, and the abstracts often omit doses, group sizes and p-values [1][2][3]. No study cited here measures Cartalax levels in human blood or cartilage [2][4]. The one human study is the periodontal trial, and it tested a multi-product regimen [6].
Research in detail
Controlled clinical study with a parallel conventional-treatment control and 12-month follow-up · 157 patients with generalized periodontitis in the main group and 133 controls, grouped by ABO blood type and disease grade
The O(I) main group improved at one year: total protein fell 34.27 percent, C-reactive protein fell 47.93 percent, and calcium rose 92.96 percent. Cartalax was given to the grade II and III groups as part of a multi-component regimen.
Evidence scope: Cartalax was one of several products and the paper does not separate its effect; allocation is not described as randomized or blinded, and the paper does not report adverse events or safety monitoring.
Primary chondrocyte culture from young and old rats with a five-day cell growth curve · Chondrocytes from 3-month-old and 20-month-old rats
Cartalax at 200 ng/ml increased chondrocyte number 1.4 to 1.8 fold in young-rat cultures and 1.6 to 2.1 fold in old-rat cultures; the cartilage polypeptide complex needed 2000 ng/ml for a comparable effect.
Evidence scope: In vitro only; the full text reports p<0.01 versus control but not replicate counts, and the authors are from the institute that developed the peptide.
Human mesenchymal stem cell culture aged by replication, with gene expression and protein synthesis assays · Human mesenchymal stem cells during replicative aging
Cartalax at 200 ng/ml activated gene expression and protein synthesis of SOX9, aggrecan, type II collagen and COMP; the cartilage complex needed 2000 ng/ml.
Evidence scope: Abstract only; donor number, passage count and statistics are not in the abstract, and the study measures markers in culture rather than cartilage repair.
Cultured chondrocyte experiment comparing Cartalax and a cartilage polypeptide complex · Chondrocytes with an aging-associated secretory phenotype
Cartalax normalized the synthesis of p16, p21, p53, TNF-alpha, IL-1alpha and SIRT1.
Evidence scope: Abstract only; species, donor age, sample size and statistics are not stated, and the markers are surrogates rather than joint outcomes.
Preclinical histological and morphometric study of mandibular bone defects · Old rats with a standard mandibular defect
Kartalaks given before surgery produced a more mature regenerate at 60 to 120 days, with less connective and cartilage tissue and more advanced bone remodeling than control.
Evidence scope: Abstract only; animal numbers, dose and route are not in the abstract, and the first author is at the St. Petersburg Institute of Bioregulation and Gerontology.
Ovariectomized rat model of osteoporosis with bone mineral density measurement · Aging female rats after ovariectomy
The cartilage preparation and T-31 both protected bone mineral density; the cartilage preparation was significantly more effective.
Evidence scope: Abstract only; the abstract does not report doses, group sizes or p-values.
Human skin fibroblast culture during replicative aging, with immunocytochemistry and confocal microscopy · Human skin fibroblasts aged in culture
Cartalax activated synthesis of SIRT1, SIRT6 and collagen I.
Evidence scope: In vitro only; the abstract gives no donor count or statistics, and the first author is at the St. Petersburg Institute of Bioregulation and Gerontology.
Rat model of cisplatin-induced acute renal failure with urinary and blood measurements · Rats with cisplatin-induced acute kidney injury
Cartalax decreased protein excretion and urinary electrolyte concentration; the polypeptide complex, Ovagen and epitalon normalized urine output, glomerular filtration rate and sodium reabsorption.
Evidence scope: Abstract only; dose and group sizes are not reported, and Cartalax affected fewer parameters than the other peptides, so the result does not establish a Cartalax-specific kidney benefit.
History and where it stands today
Cartalax has a laboratory history but no clinical development program, so the timeline is mostly a series of cell and animal studies from one research network.
- 2007Povorozniuk and colleagues reported that a cartilage-tissue preparation and the T-31 tripeptide both protected bone mineral density in ovariectomized rats, with the cartilage preparation stronger [1].
- 2014Khavinson's group reported that Cartalax raised SIRT6 and lowered p16, p21 and p53 in aging kidney cell cultures, and built a DNA minor-groove binding model for the peptide [11].
- 2016In old rats with mandibular defects, Kartalaks given before surgery produced a more mature bone regenerate at 60 to 120 days than control [13].
- 2020Cartalax increased SIRT1, SIRT6 and collagen I in aging human skin fibroblasts, adding a skin-repair signal to the cartilage work [7].
- 2021A systematic review from the same group listed Cartalax as a regulator of cartilage and skin fibroblast function [14].
- 2022A controlled study of 157 periodontitis patients gave Cartalax capsules to the grade II and III groups as part of a multi-product regimen and reported improved oral-fluid markers over 12 months [6].
- 2023Three papers reported higher chondrocyte proliferation, normalized SASP markers and activated cartilage genes in aging cells [2][3][4].
- October 2026Cartalax remains outside FDA's 503A list and has no registered trial listed on ClinicalTrials.gov [19][20]. WADA's S0 class covers unapproved substances, and the NCAA list does not name it [17][18]. See the NCAA page for that class.
How it compares with related peptides
Epitalon is a four-amino-acid peptide from the same Khavinson program, studied for neuroendocrine function, circadian rhythm and aging [14]. Cartalax is one amino acid shorter and is studied for cartilage and bone [2][13], so the two share a design philosophy but have different tissue focuses [14].
Vilon is a two-amino-acid peptide from the same family, studied for immune function [14]. It is smaller than Cartalax and has a different tissue focus, which makes the pair a useful comparison for how much selectivity a short peptide can carry [14].
Livagen is a four-amino-acid peptide studied for liver effects [15]. Cartalax is a tripeptide studied for cartilage, and both compounds come from the same small research network [15].
Side effects and safety signals
The safety record is thin, and most of what is known comes from cell and animal work rather than from treated patients.
- The 2022 periodontal study does not report adverse events; Cartalax capsules were given to patients with grade II or III disease as part of a multi-product regimen, and the paper does not describe safety monitoring [6].
- The sources reviewed contain no published toxicology, genotoxicity or human pharmacokinetic study of Cartalax, so the safe dose range and long-term profile are unknown [6][14].
- A theoretical concern is cell proliferation: Cartalax raised chondrocyte numbers and fibroblast proliferation markers in culture, and no cited study tested whether that could drive unwanted tissue growth in a living animal [2][16].
- The 2007 and 2016 rat studies report bone and cartilage effects but no clinical chemistry, organ-wide histology or mortality data in their abstracts [1][13].
- The abstract of a 2023 review asserts oral use in older osteoarthritis patients but gives no trial citation, sample size or design, so the human safety experience behind it cannot be checked from the abstract [5].
The future: what's next for Cartalax
No registered or recruiting trial of Cartalax is listed on ClinicalTrials.gov as of October 2026 [20]. The 2023 Vrach paper describes an ongoing phase 2 program for the cartilage polypeptide complex that contains the tripeptide in gonarthrosis, knee osteoarthritis, but that program tests the complex rather than the isolated tripeptide and gives no NCT number [2]. A Cartalax-alone study would need a pharmacokinetic arm, because no cited work measures how much intact peptide reaches blood or cartilage [14][15].
The human question is whether the cell and animal signals become a clinical benefit. A randomized trial in knee osteoarthritis would need pain, function and imaging outcomes, not only oral-fluid markers, and it would need to separate Cartalax from any companion products [6]. The 2022 periodontal study followed patients for a year after short treatment courses, but its design cannot attribute the improvement to Cartalax [6].
Cartalax has no FDA approval and is not on FDA's 503A bulk substances list [19][21]. WADA's S0 class covers unapproved substances, and the NCAA peptide-hormone class has a catch-all for related substances, so the anti-doping status remains restrictive even without a named entry [17][18].
- Whether intact Cartalax reaches cartilage after oral or injected use, and at what concentration, is unmeasured in humans [14][15].
- Which molecular target explains the gene-expression changes, given that the DNA-binding evidence is modeling rather than a solved structure [11][14].
- Whether the chondrocyte and bone results in rats translate into measurable cartilage repair or pain relief in humans is untested [2][13].
- Whether increased cell proliferation in culture carries any risk of unwanted tissue growth with long-term use is unknown [2][16].
- Whether a trial can separate Cartalax from the other products in the periodontal regimen, or from the cartilage complex that contains it, is a design problem that no cited study solves [2][6].